Pulmonx Corp (LUNG) stock
LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/3040% below fair value
$2.86−0.14 (-4.67%)
Close on Nov 13, 2026Market cap $122.83MP/E –Yield –
Pulmonx r&d expenses
Research and development expenses are spending on new products and technology.
Pulmonx's R&D Expenses for the twelve months ending Sep 30, 2026 was $19.38M, up 2.5% year over year. For fiscal 2025 it was $19.49M, up 10.9% from the year before. The highest annual figure on record is $19.49M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.49M | +10.9% |
| FY2024 | Dec 31, 2024 | $17.57M | -2.8% |
| FY2023 | Dec 31, 2023 | $18.08M | +17.4% |
| FY2022 | Dec 31, 2022 | $15.40M | +17.9% |
| FY2021 | Dec 31, 2021 | $13.06M | +75.1% |
| FY2020 | Dec 31, 2020 | $7.46M | +23.3% |
| FY2019 | Dec 31, 2019 | $6.05M | -13.5% |
| FY2018 | Dec 31, 2018 | $6.99M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.86M | +0.4% |
| Q2 FY2026 | Jun 30, 2026 | $5.03M | -5.1% |
| Q1 FY2026 | Mar 31, 2026 | $4.90M | +3.0% |
| Q4 FY2025 | Dec 31, 2025 | $4.58M | +14.5% |
| Q3 FY2025 | Sep 30, 2025 | $4.85M | +29.4% |
| Q2 FY2025 | Jun 30, 2025 | $5.31M | -5.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.76M | +13.0% |
| Q4 FY2024 | Dec 31, 2024 | $4.00M | +2.7% |
| Q3 FY2024 | Sep 30, 2024 | $3.74M | -11.3% |
| Q2 FY2024 | Jun 30, 2024 | $5.62M | -1.7% |
| Q1 FY2024 | Mar 31, 2024 | $4.21M | -1.0% |
| Q4 FY2023 | Dec 31, 2023 | $3.90M | -0.2% |
| Q3 FY2023 | Sep 30, 2023 | $4.22M | -3.3% |
| Q2 FY2023 | Jun 30, 2023 | $5.71M | +58.9% |
| Q1 FY2023 | Mar 31, 2023 | $4.25M | +20.3% |
| Q4 FY2022 | Dec 31, 2022 | $3.90M | +5.3% |
| Q3 FY2022 | Sep 30, 2022 | $4.37M | +55.1% |
| Q2 FY2022 | Jun 30, 2022 | $3.59M | +2.5% |
| Q1 FY2022 | Mar 31, 2022 | $3.53M | +16.5% |
| Q4 FY2021 | Dec 31, 2021 | $3.71M | +50.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.82M | +41.0% |
| Q2 FY2021 | Jun 30, 2021 | $3.51M | +145.9% |
| Q1 FY2021 | Mar 31, 2021 | $3.03M | +93.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.47M | +54.2% |
| Q3 FY2020 | Sep 30, 2020 | $2.00M | +42.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.43M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.57M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.60M | – |
| Q3 FY2019 | Sep 30, 2019 | $1.40M | – |
See a number that looks wrong?